IntelliProve
Software that estimates health parameters from a short video of a person’s face using an ordinary camera.
Website: https://intelliprove.com
Cover Block
Open sources
| Field | Value |
|---|---|
| Name | IntelliProve |
| Tagline | Software that estimates health parameters from a short video of a person’s face using an ordinary camera. [LinkedIn] |
| Headquarters | Ghent, Belgium [LinkedIn] |
| Founded | 2021 [Startup Researcher, November 2026] |
| Stage | Seed [Tech.eu, January 2025] |
| Business model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (4): Joeri Tulkens, Maxime Mattelin, Brecht Dhuyvetters, Tanguy Sanglet [IntelliProve] |
| Funding label | Seed |
| Total disclosed | $2.33M [Tracxn] |
Links
Open sources
- Website: https://intelliprove.com/
- LinkedIn: https://www.linkedin.com/company/intelliprove
What an Investor Needs First
PUBLIC IntelliProve builds software that estimates health parameters from a short facial video using an ordinary camera, and it merits investor attention now because recent financing and broader device ambitions suggest the company is trying to move from virtual care software into a wider health sensing infrastructure layer [LinkedIn] [The Next Web, November 2026] [Startup Centrum, November 2026]. Founded in Ghent in 2021, the company presents a device-light approach to remote monitoring, with company materials and external coverage describing measurements such as heart rate, HRV, breathing, blood pressure, and stress-related signals derived from a roughly 30-second face scan rather than dedicated medical hardware [LinkedIn] [IntelliProve] [The Next Web, November 2026].
The product differentiation, on the public record, rests less on a new consumer app and more on embeddable software for care providers, insurers, wellbeing platforms, and other partners that want health sensing inside their own workflows [Startup Centrum, November 2026] [Startup Researcher, November 2026]. That integration-led model is also the basis for the company's scale claim, with IntelliProve saying its technology is active in more than 50 countries, although that figure is still best treated as company-linked and coverage-repeated rather than independently audited [The Next Web, November 2026] [Supernova Fest] [Source from Flanders].
The founding bench is unusually broad for a company at this stage: Joeri Tulkens and Maxime Mattelin are listed as co-CEOs, with Brecht Dhuyvetters as chief product officer and Tanguy Sanglet as CTO [IntelliProve] [Tech Funding News, November 2026]. Public materials also tie Tulkens to a pharmaceutical sciences background at Ghent University, which is relevant to the company's clinical positioning, though the rest of the team biographies remain lightly documented in independent sources [LinkedIn, retrieved 2026] [HealthNerd Podcast, retrieved 2026].
On funding, the cleanest public read is a seed-stage company financed across multiple announced rounds, including €1 million in 2022, €1.25 million in January 2025 led by Miles Ahead, and €2.7 million in November 2026, also led by Miles Ahead, with participation from Wit-Gele Kruis and imec.istart Fund according to coverage [Tech Funding News, November 2026] [Tech.eu, January 2025] [The Next Web, November 2026]. The business model is described as SaaS, and the current hiring mix across engineering, product, and go-to-market roles is consistent with a company still building both product depth and commercial capacity rather than one already in a mature scaling phase [IntelliProve, Company] [LinkedIn].
Over the next 12 to 18 months, the key public watchpoints are not conceptual interest in camera-based health sensing but proof of repeatable deployment quality: clearer evidence on customer retention, regulatory scope beyond cited CE and ISO references, and whether expansion into robots and other connected devices creates a real second distribution channel or remains exploratory [RobotToday] [Robotics 24/7] [Startup Centrum, November 2026]. If the company can pair its integration footprint with harder third-party validation of accuracy and clinical utility, the market narrative should become easier for growth investors to underwrite [IntelliProve] [Startup Researcher, November 2026].
Partially corroborated -- Relies on a mix of company materials, LinkedIn, and named financing coverage; funding is corroborated by multiple outlets, while product performance and deployment breadth remain partly company-sourced.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Total disclosed about $2.33M over 3 rounds [Tracxn] |
Inside the Company
PUBLIC IntelliProve presents as a 2021-vintage healthtech software company built around a specific claim: health parameters can be estimated from a short facial video captured by an ordinary camera [Crunchbase] [LinkedIn]. The company is headquartered in Ghent, Belgium, according to its Crunchbase profile, and its public company materials identify four co-founders: Joeri Tulkens and Maxime Mattelin as co-CEOs, Brecht Dhuyvetters as chief product officer, and Tanguy Sanglet as chief technology officer [Crunchbase] [IntelliProve].
The public record on formation is still fairly lean, which is typical at this stage. What is clear from company and profile pages is the basic chronology: IntelliProve was founded in 2021, positioned itself as a SaaS healthtech company, and has described its core product consistently as software that turns a brief face scan into health and wellbeing signals rather than relying on dedicated hardware [Crunchbase] [LinkedIn] [IntelliProve].
A second milestone visible in company materials is the maturation of the product and compliance narrative. IntelliProve says its system can surface signals such as heart rate, HRV, breathing, and blood pressure from a 30-second scan, and it also states that its information security management system is ISO 27001 certified [IntelliProve]. Those are company-sourced claims rather than independently validated operating metrics, but they help frame where the business sits today: beyond concept stage, with a defined product surface and an enterprise-readiness message already present in its public materials [IntelliProve].
Partially corroborated -- Confirmed in part by Crunchbase, LinkedIn, and the company website; chronology and product positioning rely materially on company-controlled sources.
Under the Hood
MIXED
The product story is straightforward, which helps. IntelliProve says its software estimates health parameters from a short video of a person’s face, using an ordinary camera rather than dedicated sensing hardware [LinkedIn] [IntelliProve]. Company materials describe a 30-second face scan that returns signals including heart rate, heart rate variability, breathing, and blood pressure, and they also position the system as a source of objective biomarkers for mental health [IntelliProve]. Public descriptions from LinkedIn and the company site are directionally consistent on the core claim, but the underlying performance characteristics are not independently detailed in the reviewed sources.
The evidence also points to a broad device footprint, though most of that evidence remains company-led. IntelliProve describes the technology as a health sensing layer that can run across smartphones, tablets, smart glasses, and health kiosks [LinkedIn, retrieved 2026] [IntelliProve]. Press coverage in late 2026 adds that the company is extending the same camera-based approach beyond virtual care and mobile use cases toward connected devices and humanoid robots, which is publicly announced rather than inferred [The Next Web, November 2026] [Startup Centrum, November 2026] [Robotics 24/7].
The compliance and infrastructure picture is somewhat clearer than the clinical one. IntelliProve states that its Information Security Management System is ISO 27001 certified, and separate coverage also describes the company as ISO 27001 or ISO/IEC 27001 certified [IntelliProve] [Startup Centrum, November 2026] [RobotToday]. Sources also indicate that the software has a CE mark, while one report says the company is progressing toward CE marking as a Class IIa medical device under the EU Medical Device Regulation, which suggests the regulatory scope may still be evolving across product versions or claims [RobotToday] [Robotics 24/7]. On the stack, current hiring for backend and cloud engineering, computer vision, and senior machine learning roles supports a fairly standard software architecture assumption, but any deeper stack description would be speculative and should be treated as inferred from job postings rather than disclosed by the company [IntelliProve] [LinkedIn].
Claim stands unchecked -- This section relies materially on company website and LinkedIn product claims, with partial corroboration from The Next Web, Startup Centrum, and RobotToday on device expansion and certifications.
Market Research
PUBLIC The market matters now because IntelliProve sits at the intersection of remote care, digital health engagement, and camera-based sensing, three areas where adoption has moved faster than reimbursement and clinical standardization [The Next Web, November 2026] [Startup Centrum, November 2026].
There is no cited third-party TAM, SAM, or SOM in the source set for IntelliProve itself, so the market has to be framed through adjacent categories rather than direct sizing claims. The public evidence supports a narrower description: IntelliProve sells software into virtual-care providers, health insurers, wellbeing platforms, and other organizations that want to add measurement through an ordinary camera rather than dedicated hardware [Startup Centrum, November 2026] [LinkedIn]. That places the company inside the broader remote monitoring and digital health infrastructure stack, but its practical entry point appears to be feature integration for existing platforms, not a stand-alone consumer health app [The Next Web, November 2026] [Startup Researcher, November 2026].
Demand drivers are visible even in the limited reporting. IntelliProve is described as a way to capture heart rate, HRV, breathing, blood pressure, and stress-related signals from a short facial video, which addresses a basic friction in remote monitoring: many programs still depend on separate devices, user adherence, and logistics around hardware distribution [IntelliProve] [LinkedIn] [IntelliProve, Security]. If that camera-first workflow performs adequately in deployment, it could appeal to insurers and virtual-care operators that want lower setup friction and broader geographic reach, a possibility that aligns with the company's claim of activity in more than 50 countries [The Next Web, November 2026] [Source from Flanders].
The adjacent markets are arguably as important as the core one. Public materials place IntelliProve in virtual care and wellbeing today, while more recent coverage points to expansion into connected devices and humanoid robots, which shifts the frame from telehealth software toward embedded sensing infrastructure for any camera-equipped endpoint [Startup Centrum, November 2026] [Robotics 24/7] [The Next Web, November 2026]. That matters because the substitute set is broad: wearables, home diagnostic devices, cuff-based blood pressure tools, and software vendors that treat questionnaires or passive app data as proxies for health status all compete for the same budgets, even if they use different modalities [LinkedIn] [IntelliProve].
Regulation is likely to shape the market more than distribution alone. IntelliProve states that its information security management system is ISO 27001 certified, and third-party coverage says the software has a CE mark while the company works toward Class IIa medical device positioning under the EU Medical Device Regulation [IntelliProve, Trust Center] [RobotToday] [Robotics 24/7]. For buyers in healthcare and insurance, those trust and compliance signals can be a prerequisite to procurement rather than a growth accelerant, especially when the product touches health measurements that may influence care pathways [Startup Centrum, November 2026] [IntelliProve, Security].
| Market lens | What public sources support | Why it matters |
|---|---|---|
| Core market | Virtual-care, insurance, and wellbeing platforms embedding camera-based health sensing [Startup Centrum, November 2026] | Suggests a B2B software wedge tied to existing digital health distribution |
| Adjacent market | Remote monitoring through ordinary cameras rather than dedicated hardware [LinkedIn] [The Next Web, November 2026] | Positions IntelliProve against device-heavy monitoring workflows |
| Expansion market | Connected devices and humanoid robots with cameras [Startup Centrum, November 2026] [Robotics 24/7] | Broadens the possible endpoint base, but also expands execution risk |
| Geographic footprint signal | Technology reported active in more than 50 countries [The Next Web, November 2026] [Source from Flanders] | Implies cross-border applicability, though not revenue depth |
The table underscores a simple point: the public case is stronger on where the product can slot into existing workflows than on the size of the revenue pool it can capture. That is workable for a seed-stage company, but investors should recognize that the market definition remains adjacency-based rather than supported by a clean, third-party sizing framework in the available sources.
Partially corroborated -- Section relies on named publisher coverage and company materials, but lacks independent third-party market sizing specific to IntelliProve's category.
Competition and Substitutes
MIXED IntelliProve appears to sit in a narrow but increasingly crowded layer of digital health infrastructure: camera-based health sensing that can be embedded into another company’s app, workflow, or device, rather than sold as a standalone wearable or clinical instrument [LinkedIn] [Startup Centrum, November 2026].
The available public record does not name direct startup competitors, so the competitive map has to be drawn from adjacent categories rather than a clean peer set. On one side are incumbents in remote patient monitoring and digital biometrics, which generally rely on dedicated hardware, wearables, or regulated medical devices rather than an ordinary camera workflow. On another are virtual-care and wellbeing platforms that could treat camera-based measurement as a feature rather than a category, particularly if they already control patient traffic and can bundle monitoring into a broader service stack. A third flank is device and robotics makers, where IntelliProve is now positioning its software as a sensing layer for connected systems with cameras, including humanoid robots, according to company and media coverage [The Next Web, November 2026] [Startup Centrum, November 2026] [Robotics 24/7].
What stands out in IntelliProve's favor is not scale, which remains lightly evidenced in public sources, but product form factor. The company says its software can turn a short facial video into heart rate, HRV, breathing, and blood pressure signals, and that it can run across smartphones, tablets, smart glasses, kiosks, and other camera-equipped systems [IntelliProve] [Pieter Byn - LinkedIn, retrieved 2026]. If that portability holds up in buyer deployments, it gives IntelliProve a distribution argument that hardware-tied monitoring vendors do not have: the customer can add sensing without shipping a new device. That edge looks meaningful but perishable. It is meaningful because integration friction is often lower than hardware procurement, but perishable because software-only sensing is easier for larger platforms or better-capitalized healthtech vendors to imitate than a proprietary physical device, especially if they already own the end-user relationship.
The company also has some early trust markers that matter in healthtech, though the evidence here is still uneven. IntelliProve states that its information security management system is ISO 27001 certified, while third-party coverage has described the software as CE marked and also reported that the company is progressing toward a Class IIa medical device position under the EU Medical Device Regulation [IntelliProve, Security] [IntelliProve, Trust Center] [RobotToday] [Robotics 24/7]. Those signals can help in insurer, provider, and enterprise procurement, where security and regulatory posture often decide whether a pilot moves into production. The durability of that edge depends on whether the company can convert certifications into embedded commercial relationships. Certifications alone are rarely a moat, but they can slow newer entrants that have not yet built compliance infrastructure.
The exposure is easier to identify than the direct challenger set. IntelliProve does not appear, from the cited public material, to own a patient channel, a payer channel, or a flagship hardware platform. That leaves it dependent on partners such as virtual-care providers, insurers, wellbeing platforms, and device makers for distribution, which can compress pricing power and leave the sensing layer vulnerable to replacement if a platform develops its own measurement capability or switches vendors [Startup Centrum, November 2026]. Wit-Gele Kruis is strategically relevant here, not as a competitor but as a signal that care-delivery investors may see value in the model [The Next Web, November 2026]. The counterpoint is that an investor relationship is not the same as secured channel control, and the current source set does not establish exclusivity, major customer concentration, or long-term deployment contracts.
The most plausible 18-month scenario is a contest between horizontal embedability and channel ownership. IntelliProve is the likely winner if buyers continue to prefer camera-first monitoring that can be added to existing apps and devices without new hardware, and if its claimed footprint in more than 50 countries translates into referenceable production deployments rather than broad but shallow integrations [The Next Web, November 2026] [Supernova Fest] [Source from Flanders]. The likely loser in that scenario would be hardware-dependent remote monitoring vendors whose economics rely on shipping dedicated equipment into lower-acuity use cases. The opposite scenario is also easy to picture: virtual-care platforms or large device makers win if they decide that camera-based sensing should be native, not licensed. In that case IntelliProve would be the loser if its differentiation rests mainly on implementation speed and compliance posture rather than on exclusive data, protected IP, or hard-to-replicate clinical validation. Public sources do not yet show enough evidence to call those deeper moats established.
Opportunity
PUBLIC
The prize here is not a point solution for remote vitals, but a software layer that lets any camera become a health-sensing interface across care, insurance, wellbeing, and eventually device categories that already have distribution at global scale [LinkedIn] [Startup Centrum, November 2026] [The Next Web, November 2026].
The headline opportunity is straightforward. If IntelliProve can make camera-based health measurement accurate enough, compliant enough, and easy enough to embed, it could become infrastructure rather than an app, meaning the company sits inside other platforms instead of having to acquire end users one by one [LinkedIn] [Startup Centrum, November 2026]. That is what makes the upside reachable rather than purely conceptual. Public reporting already places the product inside platforms operating in more than 50 countries, while company materials describe a broad device surface that runs from smartphones and tablets to kiosks and smart glasses [The Next Web, November 2026] [IntelliProve] [LinkedIn, retrieved 2026]. The financing base also matters. The latest reported seed round was led by Miles Ahead, with participation from healthcare-linked backers including Wit-Gele Kruis and imec.istart Fund, which is at least directionally consistent with a company trying to sell into regulated or trust-sensitive workflows rather than consumer novelty [The Next Web, November 2026] [Tech Funding News, November 2026].
That upside breaks into a small number of credible paths. The evidence does not yet support a single dominant route, but it does support several adjacent ones.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Embedded health API for digital care | IntelliProve becomes a standard SDK or API inside virtual-care, insurer, and wellbeing products, monetizing per seat, per scan, or enterprise SaaS contracts | Wider adoption by virtual-care and insurance platforms already cited as target buyers [Startup Centrum, November 2026] | The company already describes those channels as current buyers, and reported deployment in more than 50 countries suggests early cross-border portability [Startup Centrum, November 2026] [The Next Web, November 2026] |
| Compliance-led expansion into medical workflows | The company moves from wellness and engagement use cases into higher-trust clinical pathways as CE-marking progresses | Successful advancement of the reported Class IIa MDR process and broader recognition of the software's CE-marked status [Robotics 24/7] [RobotToday] | Public sources already tie the product to a CE mark and report work toward Class IIa medical-device positioning, which would widen the set of workflows where buyers can justify deployment [RobotToday] [Robotics 24/7] |
| Camera health layer for new hardware categories | IntelliProve becomes the sensing layer for connected devices beyond phones, starting with robots, kiosks, and other vision systems | Named hardware partnerships or commercial launches in robotics and camera-equipped devices | The company and funding coverage both point to expansion from smartphones into robots and other camera-based systems, and company materials already describe operation across multiple device types [Startup Centrum, November 2026] [The Next Web, November 2026] [LinkedIn, retrieved 2026] |
Compounding, if it appears, should come from integration depth rather than consumer brand. A buyer that embeds one health signal into its workflow can add more over time, especially since company materials present the product as a sensing layer that can output heart rate, HRV, breathing, blood pressure, and mental-health-related biomarkers from the same short facial scan [IntelliProve] [IntelliProve, Health assessment through face analysis]. That creates a plausible expansion motion inside each account, where one use case such as check-in screening or wellness monitoring turns into a broader measurement stack.
There is also an early distribution flywheel visible in the public record. IntelliProve says it is active in more than 50 countries, and public hiring includes backend, computer vision, machine learning, product, and go-to-market roles, which suggests the company is staffing for both product breadth and commercial follow-through rather than a static pilot phase [Supernova Fest] [Source from Flanders] [IntelliProve, Company] [LinkedIn]. Security credentials matter here as well. The company states that its ISMS is ISO 27001 certified, and third-party coverage also references ISO 27001, which, if buyers accept it as table stakes, can shorten security review cycles and make each new integration easier to win than the last [IntelliProve, Security] [RobotToday].
The size of the win is best framed qualitatively because the available research does not include a named market-size report or a directly comparable public peer with a cited market capitalization. Even so, the public setup supports a concrete upside case. If the embedded-health-API scenario takes hold across digital care, insurers, and connected-device channels, IntelliProve could plausibly become a strategic infrastructure asset for larger healthtech, diagnostics, remote-monitoring, or device companies that want camera-based sensing without building the core stack themselves (scenario, not a forecast) [Startup Centrum, November 2026] [The Next Web, November 2026]. In that outcome, the value would come less from one application and more from control of a reusable sensing layer that can travel across geographies, customers, and hardware categories.
Partially corroborated -- This section relies on a mix of named-publisher coverage and company materials, with core upside premises supported by The Next Web, Startup Centrum, and Tech Funding News, but several product breadth and certification details remain company-asserted or single-source.
Sources
Open sources
[LinkedIn, retrieved 2026] IntelliProve | LinkedIn | https://www.linkedin.com/company/intelliprove
[The Next Web, November 2026] IntelliProve raises €2.7M to take its face scan health check to robots | https://thenextweb.com/news/intelliprove-2-7m-seed-face-scan-humanoid-robots
[Startup Centrum, November 2026] IntelliProve raises €2.7M | https://media.startupcentrum.com/en/intelliprove-raises-e2-7m/
[Startup Researcher, November 2026] IntelliProve Raises €2.7 Million Seed Round | https://www.startupresearcher.com/news/intelliprove-raises-2-7-million-seed-round
[IntelliProve] Health assessment through face analysis - IntelliProve | https://intelliprove.com/
[Tech Funding News, November 2026] IntelliProve raises €2.7M from Miles Ahead to turn any camera into a health sensor | https://techfundingnews.com/intelliprove-raises-e2-7m-from-miles-ahead-to-turn-any-camera-into-a-health-sensor/
[LinkedIn, retrieved 2026] Joeri Tulkens, PhD - IntelliProve | LinkedIn | https://www.linkedin.com/in/joeritulkens/
[HealthNerd Podcast, retrieved 2026] Die met Joeri Tulkens | https://open.spotify.com/episode/6nMMiDUYgUBUGTKg9UdRv7
[Tech.eu, January 2025] IntelliProve secures €1.25 million to expand camera-based health monitoring technology | https://tech.eu/2025/01/22/intelliprove-secures-eur1-25-million-to-expand-camera-based-health-monitoring-technology/
[RobotToday] IntelliProve | https://www.robottoday.com/news/intelliprove
[Crunchbase] IntelliProve - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/intelliprove
[LinkedIn, retrieved 2026] Pieter Byn - Ghent Metropolitan Area | Professional Profile | LinkedIn | https://www.linkedin.com/in/pieter-byn-5914101/
[Robotics 24/7] IntelliProve brings health sensing layer to humanoid robots | https://www.robotics247.com/article/intelliprove_brings_health_sensing_layer_to_humanoid_robots
[Tracxn] IntelliProve | https://tracxn.com/d/companies/intelliprove
[Supernova Fest] IntelliProve | https://www.supernovafest.eu/company/intelliprove
[Source from Flanders] IntelliProve | https://www.sourcefromflanders.com/intelliprove
Articles about IntelliProve
- IntelliProve Convinced a Belgian Nursing Giant to Back Its Camera-Only Vitals — The Belgian startup's software, which reads heart rate and blood pressure from a facial video, has secured Class IIa medical device status in the EU and is expanding to robots.